PARP INHIBITORS IN PROSTATE CANCER – RECENT UPDATES AND IMPLICATIONS FOR CLINICAL PRACTICE 2023 Bellevue United States
This CME-accredited activity is designed to provide expert interpretation of new and emerging data on the treatment of prostate cancer with PARP inhibitors (PARPi) as a single agent or potential new combination treatments in the maintenance setting. Expert faculty will discuss the essentials of clinical trial data and current and emerging treatment strategies and place them within a practical and contemporary clinical context for developing and maintaining updated care pathways for patients with advanced prostate cancer. The goal of this activity is to improve knowledge and advance the ability of oncology providers to apply current and emerging treatment strategies with PARPi to the clinical Practice in improving outcomes of patients with prostate cancer.
PARP INHIBITORS IN PROSTATE CANCER – RECENT UPDATES AND IMPLICATIONS FOR CLINICAL PRACTICE 2023 Bellevue United States
